Characteristics for patients 55 to 76 years old
| Characteristics . | Offspring, N = 218 . | Matched sibling, N = 864 . | P . |
|---|---|---|---|
| Recipient age, y | |||
| Median (range) | 63 (55-76) | 63 (55-76) | .40 |
| 55-64, n (%) | 127 (58) | 536 (62) | |
| 65-76, n (%) | 91 (42) | 328 (38) | |
| Recipient sex, n (%) | .80 | ||
| Male | 129 (59) | 803 (58) | |
| Female | 89 (41) | 361 (42) | |
| Donor age, y | <.001 | ||
| Median (range) | 34 (20-55) | 61 (28-105) | |
| Disease, n (%) | .77 | ||
| AML | 192 (88) | 767 (89) | |
| ALL | 26 (12) | 97 (11) | |
| Disease status, n (%) | .05 | ||
| CR1 | 129 (59) | 587 (68) | |
| ≥CR2 | 37 (17) | 115 (13) | |
| Relapse/primary induction failure | 52 (24) | 162 (19) | |
| Disease risk index, n (%) | .99 | ||
| Low | 6 (3) | 24 (3) | |
| Intermediate | 135 (62) | 539 (63) | |
| High | 73 (33) | 285 (31) | |
| Not reported | 4 (2) | 16 (2) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 153 (70) | 49 (6) | |
| Peripheral blood | 65 (30) | 815 (94) | |
| Conditioning intensity, n (%) | .87 | ||
| Myeloablative | 60 (28) | 233 (27) | |
| Reduced intensity | 158 (72) | 631 (73) | |
| GVHD prophylaxis, n (%) | NA | ||
| CNI + MMF + PT-Cy | 218 (100) | — | |
| CNI + MMF | — | 324 (38) | |
| CNI + MTX | — | 385 (45) | |
| CNI alone | — | 155 (18) | |
| Transplant period, n (%) | <.001 | ||
| 2008-2011 | 40 (18) | 434 (50) | |
| 2012-2015 | 178 (82) | 430 (50) |
| Characteristics . | Offspring, N = 218 . | Matched sibling, N = 864 . | P . |
|---|---|---|---|
| Recipient age, y | |||
| Median (range) | 63 (55-76) | 63 (55-76) | .40 |
| 55-64, n (%) | 127 (58) | 536 (62) | |
| 65-76, n (%) | 91 (42) | 328 (38) | |
| Recipient sex, n (%) | .80 | ||
| Male | 129 (59) | 803 (58) | |
| Female | 89 (41) | 361 (42) | |
| Donor age, y | <.001 | ||
| Median (range) | 34 (20-55) | 61 (28-105) | |
| Disease, n (%) | .77 | ||
| AML | 192 (88) | 767 (89) | |
| ALL | 26 (12) | 97 (11) | |
| Disease status, n (%) | .05 | ||
| CR1 | 129 (59) | 587 (68) | |
| ≥CR2 | 37 (17) | 115 (13) | |
| Relapse/primary induction failure | 52 (24) | 162 (19) | |
| Disease risk index, n (%) | .99 | ||
| Low | 6 (3) | 24 (3) | |
| Intermediate | 135 (62) | 539 (63) | |
| High | 73 (33) | 285 (31) | |
| Not reported | 4 (2) | 16 (2) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 153 (70) | 49 (6) | |
| Peripheral blood | 65 (30) | 815 (94) | |
| Conditioning intensity, n (%) | .87 | ||
| Myeloablative | 60 (28) | 233 (27) | |
| Reduced intensity | 158 (72) | 631 (73) | |
| GVHD prophylaxis, n (%) | NA | ||
| CNI + MMF + PT-Cy | 218 (100) | — | |
| CNI + MMF | — | 324 (38) | |
| CNI + MTX | — | 385 (45) | |
| CNI alone | — | 155 (18) | |
| Transplant period, n (%) | <.001 | ||
| 2008-2011 | 40 (18) | 434 (50) | |
| 2012-2015 | 178 (82) | 430 (50) |